Invanz Disease Interactions
There are 5 disease interactions with Invanz (ertapenem).
Antibiotics (applies to Invanz) colitis
Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)
Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.
Carbapenems (applies to Invanz) renal dysfunction
Major Potential Hazard, High plausibility.
Carbapenems are primarily eliminated by the kidney. Patients with renal impairment may be at greater risk for adverse effects from carbapenems, including seizures and other central nervous system disturbances, due to decreased drug clearance. Dosage adjustments should be considered, with modifications based on degree of renal impairment and severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during therapy.
Carbapenems (applies to Invanz) CNS disorders
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Seizures
The intravenous use of carbapenems has been associated with central nervous system adverse effects such as seizures (up to 1.5%) and, less frequently, somnolence, encephalopathy, myoclonus, tremor, paresthesia, confusion, agitation, depression, and hallucinations. Therapy with carbapenems, regardless of route of administration, should be administered cautiously in patients with or predisposed to seizures or other neurologic disturbances. The normally recommended dosages should not be exceeded in such patients. In those with a known seizure disorder, anticonvulsant therapy should be continued during carbapenem therapy.
Ertapenem (applies to Invanz) hemodialysis
Moderate Potential Hazard, High plausibility.
Ertapenem is partially removed by hemodialysis. If the recommended daily dose of 500 mg is administered within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is recommended following the dialysis session. If given at least 6 hours prior to hemodialysis, no supplementary dose is needed.
Ertapenem (applies to Invanz) sodium
Moderate Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention, Hypernatremia, Hypertension
Parenteral ertapenem contains approximately 137 mg (6.0 mEq) of sodium per each gram of ertapenem activity. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
Switch to professional interaction data
Invanz drug interactions
There are 45 drug interactions with Invanz (ertapenem).
Invanz alcohol/food interactions
There is 1 alcohol/food interaction with Invanz (ertapenem).
More about Invanz (ertapenem)
- Invanz consumer information
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- Drug class: carbapenems
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Augmentin
Augmentin is a prescription antibiotic combining amoxicillin and clavulanate to treat bacterial ...
Nitrofurantoin
Nitrofurantoin is an antibiotic used to treat urinary tract infections. Learn about side effects ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Amoxicillin/clavulanate
Amoxicillin and clavulanate potassium is a combination antibiotic used to treat bacterial ...
Cefdinir
Cefdinir systemic is used for bacterial infection, bronchitis, middle ear infections, pneumonia ...
Clindamycin
Clindamycin (Cleocin) is used to treat serious infections caused by bacteria. Includes clindamycin ...
Levofloxacin
Levofloxacin is a fluoroquinolone antibiotic used to treat serious bacterial infections and prevent ...
Metronidazole
Metronidazole is an antibiotic used to fight bacteria in your body. Learn about side effects ...
Ceftriaxone
Ceftriaxone systemic is used for bacteremia, bacterial endocarditis prevention, bacterial ...
Cephalexin
Cephalexin is a cephalosporin antibiotic used to treat bacterial infections like respiratory, skin ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.